"iXCells Biotechnologies Launches iPSCore™ Platform for Generating Highly Characterized iPSC-derived Human Cell Models
• This modular system is designed to streamline the development of highly characterised human cell models derived from induced pluripotent stem cells (iPSCs).
• The iPSCore™ platform integrates advanced tools, technical expertise and industry experience to develop iPSC-derived products using ethically sourced biospecimens, including cell fractions such as PBMCs or fibroblasts from both healthy individuals and patients.
• These cells can be reprogrammed, genetically modified, and differentiated into a wide range of cell types and 3D models, tailored to specific research or therapeutic needs.
iPSCore™ Enhances Precision in Cell Characterization & Production
• Strong focus on descriptive & functional characterization, enabling broad application in downstream assays.
• Processes over 1,000 samples annually, with an impressive 96% success rate.
• Projected output growth by 2026, especially in patient-derived cell production.
Platform siginificance
• The platform places strong emphasis on both descriptive and functional characterisation, enabling its use in a variety of downstream assays.
• Currently, iPSCore™ processes over 1,000 samples each year, achieving a success rate of more than 96%.
• Output is expected to significantly increase by 2026, particularly in patient-derived cell production.
For the demand on relevant human cell models
• iXCells developed this platform in response to the growing demand for relevant human cell models, which are often not readily available and require time-consuming design and engineering.
• The system supports the creation of both standard and customised cell products, with options for off-the-shelf or made-to-order availability.
iXCells Advances iPSC Technology for Drug Development
• Pharmaceutical & biotech sectors are shifting towards alternatives to animal models.
• The FDA Modernization Act 2.0 supports non-animal drug safety & efficacy evaluation.
• iPSC-derived models are proving to be more predictive and reliable, addressing unmet medical needs.
• iPSCore™ launch showcases iXCells' commitment to harnessing iPSC technology for advanced research.
• Combines cell reprogramming, editing & differentiation to replicate human biology in vitro.
Lays the groundwork for future innovations:
• In vitro drug screening across diverse human genotypes.
• AI-powered disease pattern identification.
Moving towards ""clinical trials on a plate"".
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!